Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2008-05-13
2008-05-13
Campbell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S184100, C424S278100
Reexamination Certificate
active
10182093
ABSTRACT:
The present invention provides methods and adjuvants for enhancing an immune response to RSV in a host, wherein the methods and adjuvants comprise a source of a CD40 binding protein. Preferably, the CD40 binding protein is CD40L and the source is a vector comprising a promoter operatively linked to a CD40L coding region. The enhanced immune response produced by the adjuvants and methods of the current invention includes both increased expression of Th1 cytokines and increased production of antibody.
REFERENCES:
patent: 5811524 (1998-09-01), Brams et al.
patent: 5843913 (1998-12-01), Li et al.
patent: 5880104 (1999-03-01), Li et al.
patent: 5939068 (1999-08-01), Brams et al.
patent: WO96/26735 (1996-09-01), None
patent: WO 96/26736 (1996-09-01), None
patent: WO 98/02180 (1998-01-01), None
patent: WO 98/02457 (1998-01-01), None
patent: WO 99/43839 (1999-09-01), None
Tripp et al. J of Virology 1998 vol. 72, pp. 8971-8975.
Gurunathan et al. J. of Immunology 1998 vol. 161, pp. 4563-4571.
Murphy et al Virus Research 1994 vol. 32, pp. 13-36.
Ihata et al. “Immunomodulatory effect of a plasmid expressing CD40 ligand on DNA vaccination against human immunodeficiency virus type-1,”Immunology98: 436-442 (1999).
Maue, Alexander et al. “CD80 and CD86, but not CD154, argument DNA vaccine-induced protection in experimental bovine tuberculosis”Vaccine23:769-779 (2004).
Miyahira, Yasushi et al. “Cutting Edge: A potent adjuvant effect of ligand to receptor activator of NF-KB Gene for Inducing Antigen-Specific CD8+ T Cell Response by DNA and Viral Vector Vaccination”J Immunol. 171:6344-6348 (2003).
Allen et al., “CD40 Ligand Gene Defects Responsible for X-Linked Hyper-IgM Syndrome”Science259:990-993, Feb. 12, 1993.
Anderson et al., “Cytokine Response to Respiratory Syncytial Virus Stimulation of Human Peripheral Blood Mononuclear Cells”J. Infect. Dis.170:1201-1208, Nov. 1994.
Armitage et al., “Molecular and biological characterization of a murine ligand for CD40”Nature357:80-82, May 7, 1992.
Armitage et al., “CD4DL: a multi-functional ligand”Seminars in Immunol.5:401-412, 1993.
Aruffo et al., “The CD40 Ligand, gp39 Is Defective in Activated T Cells from Patients with X-Linked Hyper-IgM Syndrome”Cell72:291-300, Jan. 29, 1993.
Balasa et al., “CD40 Ligand-CD40 Interactions Are Necessary for the Initiation of Insulitis and Diabetes in Nonobese Diabetic Mice”J. Immunol. 159(9):4620-4627, 1997.
Banchereau et al., “The CD40 Antigen and its Ligand”Annu. Rev. Immunol. 12:881-922, 1994.
Barrett et al., “CD40 Signaling Activates CD11a/CD18 (LFA-1)-Mediated Adhesion in B Cells”J Immunol. 146(6):1722-1729, Mar. 15, 1991.
Bennett et al., “Help for a cytotoxic-T-cell responses is mediated by CD40 signalling”Nature393(4):478-480, Jun. 4, 1998.
Borrow et al., “CD40L-deficient Mice Show Deficits in Antiviral Immunity and Have an Impaired Memory CD8 CTL Response”J. Exp. Med. 183(5):2129-2142, May 1996.
Briones et al., “In Vivo Antitumor Effect of CD40L-transduced Tumor Cells as a Vaccine for B-Cell Lymphoma”Cancer Res62:3195-3199, Jun. 1, 2002.
Brown et al., “Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice”Nat. Med. 4(11):1253-1260, Nov. 1998.
Caims et al., “Soluble CD23 is released by B lymphocytes cycling in response to interleukin 4 and anti-Bp50 (CDw40)”Eur. J. Immunol. 18:349-353, 1988.
Cantwell et al., “T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154”Leukemia15:1451-1457, Sep. 2001.
Castigli et al., “CD40-deficient mice generated by recombination-activating gene-2-deficient blaslocyst complementation”Proc. Natl Acad. Sci. USA91:12135-12139, Dec. 1994.
Chaudhary et al., “A recombinant immunotoxin consisting of two antibody variable domains fused toPseudomonasexotoxin”Nature339(6223):394-397, Jun. 1, 1989.
Chin et al., “Field Evaluation of a Respiratory Syncytial Virus Vaccine and a Trivalent Parainfluenza Virus Vaccine in a Pediatric Population”Am. J. Epidemiol. 89(4):449-463, 1969.
Clupitu et al., “Immunization with a Lymphocytic Choriomeningitis Virus Peptides Mixed with Heat Shock Protein 70 Results in Protective Antiviral Immunity and Specific Cytotoxic T Lymphocytes”J. Exp. Med. 187(5):685-691, Mar. 2, 1998.
Clark et al., “Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50”Proc. Natl. Acad. Sci. USA8:4494-4498, Jun. 1986.
Clark et al., “Association Between IL-6 and CD40 Signaling: IL-6 Induces Phosphorylation of CD40 Receptors”J. Immunol.145(5):1400-1406, Sep. 1, 1990.
Collins et al., “Respiratory Syncytial Virus” in Fields B, Knipe D, Howley P., eds.,Fields Virlogy3rded, Philadelphia: Lippencott-Raven Publishers, Chapter 44 pp. 1313-1351, 1996.
Connors et al., “Enhanced Pulmonary Histopathology Induced by Respiratory Syncytial Virus (RSV) Challenge of Formalin-Inactivated RSV-Immunized BALB/c Mice Is Abrogated by Depletion of Interleukin-4 (IL-4) and IL-10”J. Virol. 68(8):5321-5325, Aug. 1994.
Connors et al., “Respiratory Syncytial Virus (RSV) F, G, M2 (22K), and N Proteins Each Induce Resistance to RSV Challenge, but Resistance Induced by M2 and N Proteins Is Relatively Short-Lived”J. Virol. 65(3):1634-1637, Mar. 1991.
Cosyns et al., “Requirement of CD40-CD40 Ligand Interaction for Elimination ofCryptosporidium parvumfrom Mice”Infec. Immun. 66(2):603-607, Feb. 1998.
Couderc et al., “Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells”Cancer Gene Ther. 5(3):163-175, 1998.
Crowe, “Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV)—A meeting report of the WHO Programme foe Vaccine Development”Vaccine13(4):415-421, 1995.
DeKruyff et al., “Antigen-Driven but Not Lipopolysaccharide-Driven Il-12 Production in Macrophages Requires Triggering of CD40”J. Immunol. 158:359-366, 1997.
Dilloo et al., “CD 40 Ligand Induces an Antileukemia Immune Response In Vivo”Blood90(5):1927-1933, Sep. 1, 1997.
Doherty, “Vaccines and cytokine-mediated pathology in RSV infection”Trends Microbiol. 2(5):148-150, May 1994.
Dolti et al., “Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells: A model for immunotherapy”Exp. Hematol. 29:952-961, Aug. 2001.
Dudas and Karron, “Respiratory Syncytial Virus Vaccines”Clin. Microbiol. Rev. 11(3):430-439, Jul. 1998.
Dullforce et al., “Enhancement of T cell-independent immune response in vivo by CD40 antibodies”Nat. Med. 4(1):88-91, Jan. 1998.
Durie et al., “The role of CD40 in the regulation of humoral and cell-mediated immunity”Immunol. Today15(9):406-410, 1994.
Falsey and Walsh, “Safety and immunogenicity of respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60”Vaccine14(13):1214-1218, Sep. 1996.
Fixler, “Respiratory Syncytial Virus Infection in Children with Cogenital Heart Disease: A Review”Pediatr.Cardiol.17:163-168, 1996.
Gascan et al., “Anti-CD40 Monoclonal Antibodies or CD4 T Cell Clones and IL-4 Induce IGG4 and IGE Switching in Purified Human B Cells via Different Signaling Pathways”J. Immunol.147(1):8-13, Jul. 1, 1991.
Gordon et al., “Resting B Lymphocytes Can Be Triggered Directly Through The CDw40 (Bp50) Antigen. A Comparison with IL-4-Mediated Signaling”J. Immunol. 140(5):1425-1430, Mar. 1, 1988.
Graham et al., “Priming Immunization Determines T Helper Cytokine mRNA Expression Patterns in Lungs of Mice C
Anderson Larry J.
Brown Michael P.
Tripp Ralph A.
Campbell Bruce R.
Hill Myron G.
Klarquist & Sparkman, LLP
The United States of America as represented by the Department of
LandOfFree
Cd40 ligand adjuvant for respiratory syncytial virus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cd40 ligand adjuvant for respiratory syncytial virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cd40 ligand adjuvant for respiratory syncytial virus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3951576